Skip to main content

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akero Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Akero Therapeutics, Inc. (“Akero” or “the Company”) (NASDAQ: AKRO) for violations of the securities laws.

According to the Complaint, the Company made false and misleading statements to the market. 20% of the patients enrolled in Akero’s SYMMETRY study suffered from cryptogenic cirrhosis and did not have definitive NASH at baseline. These patients did not have biopsy-proven compensated cirrhosis. The SYMMETRY study excluded these patients when calculating the NASH resolution secondary endpoints. The Company influenced the study’s results and increased its likelihood of failing to reach its primary endpoint by introducing confounding factors to the study. The SYMMETRY study failed to align with FDA guidance by not ruling out potential causes for each patients' cirrhosis. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Akero, investors suffered damages.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at, or by email at

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.